Related Experiment Videos
[Variations of functional parameters in chronic aggressive HBAg positive and negative hepatitis by means of
Insights
Chronic aggressive hepatitis (CAH) patients, regardless of Hepatitis B antigen (HBAg) status, exhibit similar disease characteristics. Prior immunosuppressive drug treatment in HBAg-positive and negative CAH patients correlated with lower total bilirubin levels.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Chronic aggressive hepatitis (CAH) is a severe liver inflammation.
- The role of Hepatitis B surface antigen (HBAg) in CAH pathogenesis is not fully understood.
- Investigating HBAg status and treatment effects is crucial for understanding CAH.
Purpose of the Study:
- To compare CAH patients with and without HBAg.
- To assess the impact of prior immunosuppressive treatment on CAH patients.
- To explore the relationship between HBAg, treatment, and disease characteristics.
Main Methods:
- Cross-sectional study of 43 CAH patients.
- Patients categorized based on HBAg presence (positive/negative).
- Subgroup analysis of treated (immunosuppressive drugs) versus untreated patients.
Main Results:
- No significant differences observed between HBAg-positive and HBAg-negative groups.
- Previously treated CAH patients showed significantly lower total bilirubin levels (P<0.05) compared to untreated patients.
- Other tested correlations and comparisons yielded negligible results.
Conclusions:
- CAH patients present a similar syndrome irrespective of HBAg status.
- HBAg carrier status may not drive liver disease progression; rather, liver disease might influence immune disorders.
- Further research with improved HBAg detection methods is warranted.
Abstract:
43 subjects, affected by chronic aggressive hepatitis (CAH) have been divided into two groups according to the presence of HBAg. No statistically significant differences between the two groups have been provided. The two classes of subjects (HBAg + and -) were also divided into the already treated (with immunosuppressive drugs) and untreated to investigate the eventual differences existing between the two classes. The results of this division was that previously treated subjects present a lower total bilirubin (P less than 0.05) in respect to those that were not treated previously. The results of all the other comparisons carried out and the tested correlations were negligible. In conclusion, bearing in mind the inadequate methods used up to now to research the HBAg, the transversal studies show that CAH patients are both affected by the same syndrome, whether the HBAg is positive or negative. However, it is probable that it is not the carrier state of HBAg which enables the liver disease evolution but the liver disease itself enables the cellular immunity disorders that often appear in the course of CAH.